Pulmonary Artery Catheter Market Projected to Expand 60% Through 2035

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Pulmonary artery catheter market projected to grow from $1.23B to $1.97B by 2035, driven by rising cardiovascular disease and expanding critical care infrastructure globally.

Pulmonary Artery Catheter Market Projected to Expand 60% Through 2035

The global pulmonary artery catheter market is experiencing steady expansion, with valuations expected to grow from USD 1.23 billion in 2025 to USD 1.97 billion by 2035, representing a compound annual growth rate of 4.87%. This sustained expansion reflects broader trends in critical care infrastructure and clinical demand for advanced hemodynamic monitoring technologies across healthcare systems worldwide.

Several factors are contributing to this market trajectory. The rising prevalence of cardiovascular disease, coupled with an increase in critical care procedures globally, continues to drive adoption of pulmonary artery catheters in intensive care units. Healthcare facilities are simultaneously expanding their ICU capacities to meet growing patient volumes, creating additional demand for diagnostic and monitoring equipment. The clinical emphasis on precise hemodynamic assessment in critically ill patients further reinforces the market's growth outlook.

Regionally, the United States represents a significant market segment, with projections indicating growth from USD 0.38 billion in 2025 to USD 0.58 billion by 2035. This performance reflects the mature nature of the U.S. healthcare infrastructure and the established role of hemodynamic monitoring in critical care protocols across American medical institutions.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 17

Related Coverage

GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Boston Scientific Faces Securities Lawsuit Over Electrophysiology Segment Misstatements

Boston Scientific faces class action over false electrophysiology segment statements. Investors from July 2025–February 2026 may recover damages; lead plaintiff deadline May 4, 2026.

BSX
The Motley Fool

Boone Capital Exits 372% Biotech Winner to Chase Emerging Clinical Plays

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.

MDTTYRAIONS
GlobeNewswire Inc.

Law Firm Launches Securities Fraud Investigations Into Four Public Companies

Law firm investigates securities fraud claims against ASP Isotopes, Integer Holdings, Molina Healthcare, and Soleno Therapeutics for alleged misstatements regarding technology, competitive position, medical costs, and drug safety.

ASPIITGRMOH
GlobeNewswire Inc.

ELISpot & FluoroSpot Market Set for 7.1% Growth Through 2031

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.

MRKTMOBDX
GlobeNewswire Inc.

BioCardia to Unveil 2025 Results, Corporate Strategy on March 24 Call

BioCardia scheduled conference call for March 24, 2026 to report full-year 2025 financial results and provide corporate update.

BCDA